1. Home
  2. MTH vs ACAD Comparison

MTH vs ACAD Comparison

Compare MTH & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTH
  • ACAD
  • Stock Information
  • Founded
  • MTH 1985
  • ACAD 1993
  • Country
  • MTH United States
  • ACAD United States
  • Employees
  • MTH N/A
  • ACAD 654
  • Industry
  • MTH Homebuilding
  • ACAD Biotechnology: Pharmaceutical Preparations
  • Sector
  • MTH Consumer Discretionary
  • ACAD Health Care
  • Exchange
  • MTH Nasdaq
  • ACAD Nasdaq
  • Market Cap
  • MTH 5.1B
  • ACAD 4.1B
  • IPO Year
  • MTH 1988
  • ACAD 2004
  • Fundamental
  • Price
  • MTH $67.24
  • ACAD $23.99
  • Analyst Decision
  • MTH Buy
  • ACAD Buy
  • Analyst Count
  • MTH 9
  • ACAD 21
  • Target Price
  • MTH $82.88
  • ACAD $29.10
  • AVG Volume (30 Days)
  • MTH 847.7K
  • ACAD 1.7M
  • Earning Date
  • MTH 10-28-2025
  • ACAD 11-05-2025
  • Dividend Yield
  • MTH 2.50%
  • ACAD N/A
  • EPS Growth
  • MTH N/A
  • ACAD 98.53
  • EPS
  • MTH 7.50
  • ACAD 1.54
  • Revenue
  • MTH $6,043,594,000.00
  • ACAD $1,047,118,000.00
  • Revenue This Year
  • MTH N/A
  • ACAD $14.12
  • Revenue Next Year
  • MTH $6.42
  • ACAD $11.80
  • P/E Ratio
  • MTH $9.19
  • ACAD $15.66
  • Revenue Growth
  • MTH N/A
  • ACAD 12.69
  • 52 Week Low
  • MTH $59.27
  • ACAD $13.40
  • 52 Week High
  • MTH $98.74
  • ACAD $26.65
  • Technical
  • Relative Strength Index (RSI)
  • MTH 43.49
  • ACAD 62.50
  • Support Level
  • MTH $64.99
  • ACAD $22.00
  • Resistance Level
  • MTH $69.66
  • ACAD $23.58
  • Average True Range (ATR)
  • MTH 2.13
  • ACAD 1.02
  • MACD
  • MTH 0.18
  • ACAD 0.25
  • Stochastic Oscillator
  • MTH 33.96
  • ACAD 89.47

About MTH Meritage Homes Corporation

Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising ten states: Arizona, California, Colorado, Texas, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Utah. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the homebuilding segment.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: